Search

Your search keyword '"Hamelmann, E."' showing total 734 results
Start Over Author "Hamelmann, E."
734 results on '"Hamelmann, E."'

2. Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study

Author

Guilbert TW, Murphy KR, Hamelmann E, Ross KR, Gupta A, Fiocchi A, Xia C, Gall R, Ledanois O, Radwan A, Jacob-Nara JA, Rowe PJ, and Deniz Y

Subjects
asthma, children, dupilumab, exacerbations, lung function, moderate-to-severe asthma, percent-predicted fev1, uncontrolled asthma, Immunologic diseases. Allergy, RC581-607
Abstract

Theresa W Guilbert,1 Kevin R Murphy,2 Eckard Hamelmann,3 Kristie R Ross,4 Atul Gupta,5 Alessandro Fiocchi,6 Changming Xia,7 Rebecca Gall,7 Olivier Ledanois,8 Amr Radwan,7 Juby A Jacob-Nara,9 Paul J Rowe,9 Yamo Deniz7 1Cincinnati Children’s Hospital and University of Cincinnati, Cincinnati, OH, USA; 2Boys Town National Research Hospital, Omaha, NE, USA; 3Department of Pediatrics, Children’s Center Bethel, University of Bielefeld, Bielefeld, Germany; 4UH Rainbow Babies and Children’s Hospital, Cleveland, OH, USA; 5King’s College Hospital, London, UK; 6Bambino Gesù Children’s Hospital IRCCS, Rome, Italy; 7Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 8Sanofi, Paris, France; 9Sanofi, Bridgewater, NJ, USACorrespondence: Theresa W Guilbert, Cincinnati Children’s Hospital and University of Cincinnati, Cincinnati, OH, USA, Tel +1 513-636-6771, Email theresa.guilbert@cchmc.orgBackground: Severe, uncontrolled asthma and asthma exacerbations in children are associated with abnormal lung function and airway development, and increased risk of chronic obstructive lung disease in adulthood. The rationale for this post hoc analysis was to explore the relationship between changes in asthma exacerbation rates and lung function in children treated with dupilumab.Methods: This post hoc analysis included children aged 6 to 11 years with uncontrolled, moderate-to-severe type 2 asthma (blood eosinophils ≥ 150 cells/μL or fractional exhaled nitric oxide ≥ 20 ppb) who received dupilumab or placebo in the phase 3 LIBERTY ASTHMA VOYAGE study (NCT02948959). Endpoints were the proportion of patients achieving clinically meaningful improvements (≥ 5% or ≥ 10%) in pre-bronchodilator percent-predicted forced expiratory volume in 1 second (ppFEV1) by Week 12, annualized severe asthma exacerbation rates from Week 12– 52, and mean change from baseline in ppFEV1 to Week 12.Results: At Week 12 of VOYAGE, 141/236 (60%) of children treated with dupilumab and 57/114 (50%) of children receiving placebo showed improvements of ≥ 5% in ppFEV1; 106/236 (45%) children receiving dupilumab and 36/114 (32%) receiving placebo achieved improvements in ppFEV1 ≥ 10%. During the Week 12– 52 treatment period, dupilumab vs placebo significantly reduced severe exacerbation rates in all subgroups by 52– 60% (all P< 0.05). Dupilumab treatment resulted in rapid and sustained improvements in ppFEV1 (Week 12 least squares mean difference [95% CI] vs placebo: 3.54 [0.30, 6.78] percentage points; P=0.03) in children who achieved improvements of ≥ 5%.Conclusion: Dupilumab vs placebo significantly improved pre-bronchodilator ppFEV1, with a higher proportion of patients achieving a clinically meaningful response at Week 12. Dupilumab also significantly reduced severe exacerbation rates, independent of pre-bronchodilator ppFEV1 response at Week 12.Trial Registration: NCT02948959.Keywords: asthma, children, dupilumab, exacerbations, lung function, moderate-to-severe asthma, percent-predicted FEV1, uncontrolled asthma

Published
2024

11. Cost-Effectiveness Of The SQ® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective

Author

Vogelberg C, Hamelmann E, Wahn U, Domdey A, Pollock RF, and Grand TS

Subjects
rhinitis, allergic, asthma, costs and cost analysis, germany, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Christian Vogelberg,1 Eckard Hamelmann,2 Ulrich Wahn,3 Anne Domdey,4 Richard F Pollock,5 Tobias S Grand4 1Technische Universität Dresden, Dresden, Germany; 2Klinik Für Kinder- und Jugendmedizin, Evangelisches Klinikum Bethel GmbH, Akademisches Lehrkrankenhaus der Universität Münster, Bielefeld, Germany; 3Klinik Für Pädiatrie m.S. Pneumologie, Immunologie und Intensivmedizin, Charité, Berlin, Germany; 4ALK-Abelló A/S, Hørsholm, Denmark; 5Covalence Research Ltd, London, UKCorrespondence: Tobias S GrandALK-Abelló A/S, Hørsholm, DenmarkTel +45 45 74 75 76Email Tobias.SydendalGrand@alk.netBackground: The Grazax Asthma Prevention (GAP) trial has recently demonstrated significant reductions in the odds of asthma symptoms or medication use in patients treated with SQ® grass SLIT-tablet relative to placebo, both in combination with allergy and asthma pharmacotherapy. The objective of the present analysis was to evaluate the cost-effectiveness of SQ grass SLIT-tablet relative to placebo in children with AR from the perspective of a German healthcare payer.Methods: A cost-utility model was developed in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) to evaluate the cost-utility of SQ grass SLIT-tablet in combination with pharmacotherapy versus pharmacotherapy alone in patients with AR. Transition probabilities were derived from the GAP trial, and costs were taken from a real-world insurance database analysis. Future costs and effects were discounted at 3% per annum, and extensive deterministic and probabilistic sensitivity analyses were performed.Results: Over a 10-year time horizon, the base case analysis showed an increase in overall treatment costs of €897 per child being treated with SQ grass SLIT-tablet relative to pharmacotherapy alone. The increased treatment costs were accompanied by an improvement in patient quality of life of 0.10 quality-adjusted life years (QALYs) yielding an ICER of €8978 per QALY gained, falling well below a willingness-to-pay threshold of €17,800 per QALY gained. The base case results were insensitive to changes in all individual model parameters.Discussion: Improvements in quality of life with the SQ grass SLIT-tablet would be accompanied by only a modest increase in costs over a 10-year time horizon, with the SQ grass SLIT-tablet therefore representing excellent value for money from the German healthcare payer perspective.Keywords: rhinitis, allergic, asthma, costs and cost analysis, Germany

Published
2019

12. Psychometric properties of the KoCoN-V

Author

Schmidt, P., primary, Zernikow, B., additional, Hartenstein-Pinter, A., additional, Wager, J., additional, Bertolini, A., additional, Blankenburg, M., additional, Classen, G., additional, von der Hagen, M., additional, Hamelmann, E., additional, Raffler, S., additional, Schallner, J., additional, Schimmel, M., additional, Springer, S., additional, Wendel, E., additional, and Rostasy, K., additional

Published
2023
Full Text
View/download PDF

13. Diagnose und Therapie der Bienen- und Wespengiftallergie

Author

Ruëff, F., primary, Bauer, A., additional, Becker, S., additional, Brehler, R., additional, Brockow, K., additional, Chaker, A.M., additional, Darsow, U., additional, Fischer, J., additional, Fuchs, T., additional, Gerstlauer, M., additional, Gernert, S., additional, Hamelmann, E., additional, Hötzenecker, W., additional, Klimek, L., additional, Lange, L., additional, Merk, H., additional, Mülleneisen, N.K., additional, Neustädter, I., additional, Pfützner, W., additional, Sieber, W., additional, Sitter, H., additional, Skudlik, C., additional, Treudler, R., additional, Wedi, B., additional, Wöhrl, S., additional, Worm, M., additional, and Jakob, T., additional

Published
2023
Full Text
View/download PDF

14. Future perspectives of anticholinergics for the treatment of asthma in adults and children

Author

Buhl R and Hamelmann E

Subjects
asthma, anticholinergic, tiotropium, Therapeutics. Pharmacology, RM1-950
Abstract

Roland Buhl,1 Eckard Hamelmann2,3 1Pulmonary Department, Johannes Gutenberg University Hospital Mainz, Mainz, Germany; 2Children’s Center Bethel, Evangelic Hospital Bethel, Department of Pediatrics, Bielefeld, Germany; 3University Children’s Hospital, Allergy Center Ruhr, Ruhr University Bochum, Bochum, Germany Abstract: Despite major advances in therapeutic interventions and the availability of detailed treatment guidelines, a high proportion of patients with symptomatic asthma remain uncontrolled. Asthma management is largely guided by the Global Initiative for Asthma (GINA) strategy and is based on a backbone of inhaled corticosteroid (ICS) therapy with the use of additional therapies to achieve disease control. Inhaled long-acting bronchodilators alone and in combination are the preferred add-on treatment options. Although long-acting muscarinic antagonists (LAMAs) are a relatively recent addition to disease management recommendations for asthma, tiotropium has been extensively studied in a large clinical trial program. In Europe and the United States, tiotropium is approved for patients aged ≥6 years and uncontrolled on medium- to high-dose ICS/long-acting β2-agonists at GINA Steps 4 and 5 with a history of exacerbations. Evidence supports the efficacy of tiotropium Respimat® in adults in terms of lung function and asthma control, with a safety profile comparable with that of placebo across a range of asthma severities. Similarly, clinical trials in patients aged 1–17 years have shown improvements in lung function and trends toward improved asthma control. Furthermore, its efficacy makes tiotropium relatively easy to incorporate into routine clinical practice, irrespective of allergic status and without the need for patient phenotyping. Tiotropium is a cost-effective treatment that may offer an important alternative to other, more expensive add-on therapies. This review discusses the potential future position of LAMAs in clinical practice by considering the continuously evolving evidence. Prominence is given to tiotropium, the only LAMA supported by a structured clinical trial program in asthma to date, while also considering other recommended treatment options for patients with uncontrolled asthma. The importance of effective patient/caregiver–clinician communication and shared decision-making in enhancing treatment adherence is also highlighted. Keywords: asthma, anticholinergic, tiotropium, LAMA, asthma management, adherence, pediatric asthma

Published
2019

17. Performance of Pulmonary Rehabilitation in a National Severe Asthma Cohort

Author

Jarosch, I., primary, Nussbaumer, A., additional, Holtdirk, A., additional, Seefeldt, M., additional, Schneeberger, T., additional, Gloeckl, R., additional, Leitl, D., additional, Buhl, R., additional, Hamelmann, E., additional, Idzko, M., additional, Korn, S., additional, Taube, C., additional, Milger, K., additional, Skowasch, D., additional, Schulz, C., additional, Jandl, M., additional, Ehmann, R., additional, Schmidt, O., additional, and Koczulla, A.R., additional

Published
2023
Full Text
View/download PDF

20. Assessment of the long-term safety and efficacy of dupilumab in children with asthma: LIBERTY ASTHMA EXCURSION

Author

Hamelmann, E, additional, Bacharier, L, additional, Maspero, J, additional, Katelaris, C, additional, Fiocchi, A, additional, Gagnon, R, additional, De Mir, I, additional, Guilbert, T, additional, Jackson, D, additional, Li, N, additional, Akinlade, B, additional, Laws, E, additional, Mannent, L, additional, Maloney, J, additional, Tawo, K, additional, Khokhar, F, additional, Hardin, M, additional, Abdulai, R, additional, Lederer, D, additional, and Robinson, L, additional

Published
2023
Full Text
View/download PDF

22. S3-Leitlinie: Klassifikation, Diagnostik und Therapie der Urtikaria

Author

Zuberbier, T., primary, Altrichter, S., additional, Bauer, S., additional, Brehler, R., additional, Brockow, K., additional, Dressler, C., additional, Fluhr, J., additional, Gaskins, M., additional, Hamelmann, E., additional, Kühne, K., additional, Merk, H., additional, Mülleneisen, N.K., additional, Nast, A., additional, Olze, H., additional, Ott, H., additional, Pleimes, M., additional, Ruëff, F., additional, Staubach-Renz, P., additional, Wedi, B., additional, and Maurer, M., additional

Published
2023
Full Text
View/download PDF

26. Obstruktive Atemwegserkrankungen

Author

Frey, U., Gappa, M., Eber, E., von Mutius, E., Barben, J., Hammer, J., Hamelmann, E., Horak, E., Schuster, A., Hansen, G., Seidenberg, J., Modl, M., von Mutius, Erika, editor, Gappa, Monika, editor, Eber, Ernst, editor, and Frey, Urs, editor

Published
2013
Full Text
View/download PDF

30. Eine prospektive, placebo-kontrollierte multizentrische Studie zur Untersuchung der Wirksamkeit und Sicherheit von Tiotropium bei teil- und unkontrolliertem Asthma im Vorschulalter

Author

Trischler, J, additional, Donath, H, additional, Scheele, D, additional, Schaub, B, additional, Lex, C, additional, Gappa, M, additional, Lau, S, additional, Kamin, W, additional, Hamelmann, E, additional, Vogelberg, C, additional, Dahlheim, M, additional, Prenzel, F, additional, Mainz, J, additional, Müller, C, additional, Brinkmann, F, additional, Rose, M, additional, Kabesch, M, additional, Gerstlauer, M, additional, Karremann, M, additional, Schollenberger, L, additional, and Zielen, S, additional

Published
2022
Full Text
View/download PDF

31. Leitlinie zur Allergen-Immuntherapie bei IgE-vermittelten allergischen Erkrankungen

Author

Pfaar, O., primary, Ankermann, T., additional, Augustin, M., additional, Bubel, P., additional, Böing, S., additional, Brehler, R., additional, Eng, P.A., additional, Fischer, P.J., additional, Gerstlauer, M., additional, Hamelmann, E., additional, Jakob, T., additional, Kleine-Tebbe, J., additional, Kopp, M.V., additional, Lau, S., additional, Mülleneisen, N., additional, Müller, C., additional, Nemat, K., additional, Pfützner, W., additional, Saloga, J., additional, Strömer, K., additional, Schmid-Grendelmeier, P., additional, Schuster, A., additional, Sturm, G.J., additional, Taube, C., additional, Szépfalusi, Z., additional, Vogelberg, C., additional, Wagenmann, M., additional, Wehrmann, W., additional, Werfel, T., additional, Wöhrl, S., additional, Worm, M., additional, and Wedi, B., additional

Published
2022
Full Text
View/download PDF

32. Bronchodilator reversibility in the GAN severe asthma cohort

Author

Milger, K, primary, Skowasch, D, additional, Hamelmann, E, additional, Mümmler, C, additional, Idzko, M, additional, Gappa, M, additional, Jandl, M, additional, Körner-Rettberg, C, additional, Ehmann, R, additional, Schmidt, O, additional, Taube, C, additional, Holtdirk, A, additional, Timmermann, H, additional, Buhl, R, additional, and Korn, S, additional

Published
2022
Full Text
View/download PDF

34. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta‐analysis

Author

Dhami, S., Nurmatov, U., Arasi, S., Khan, T., Asaria, M., Zaman, H., Agarwal, A., Netuveli, G., Roberts, G., Pfaar, O., Muraro, A., Ansotegui, I. J., Calderon, M., Cingi, C., Durham, S., van Wijk, R. Gerth, Halken, S., Hamelmann, E., Hellings, P., Jacobsen, L., Knol, E., Larenas‐Linnemann, D., Lin, S., Maggina, P., Mösges, R., Oude Elberink, H., Pajno, G., Panwankar, R., Pastorello, E., Penagos, M., Pitsios, C., Rotiroti, G., Timmermans, F., Tsilochristou, O., Varga, E.‐M., Schmidt‐Weber, C., Wilkinson, J., Williams, A., Worm, M., Zhang, L., and Sheikh, A.

Published
2017
Full Text
View/download PDF

36. Primary Prevention of Atopy

Author

Wahn, U., Nickel, R., Illi, S., Lau, S., Grüber, C., Hamelmann, E., Ring, Johannes, editor, Przybilla, Bernhard, editor, and Ruzicka, Thomas, editor

Published
2006
Full Text
View/download PDF

40. Allergie

Author

Wahn, U., Hamelmann, E., Wahn, V., Lentze, Michael J., editor, Schulte, Franz J., editor, Schaub, Jürgen, editor, and Spranger, Jürgen, editor

Published
2003
Full Text
View/download PDF

42. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author

Bousquet J., Anto J. M., Iaccarino G., Czarlewski W., Haahtela T., Anto A., Akdis C. A., Blain H., Canonica G. W., Cardona V., Cruz A. A., Illario M., Ivancevich J. C., Jutel M., Klimek L., Kuna P., Laune D., Larenas-Linnemann D., Mullol J., Papadopoulos N. G., Pfaar O., Samolinski B., Valiulis A., Yorgancioglu A., Zuberbier T., Abdul Latiff A. H., Abdullah B., Aberer W., Abusada N., Adcock I., Afani A., Agache I., Aggelidis X., Agustin J., Akdis C., Akdis M., Al-Ahmad M., Al-Zahab Bassam A., Aldrey-Palacios O., Alvarez Cuesta E., Alzaabi A., Amad S., Ambrocio G., Annesi-Maesano I., Ansotegui I., Anto J., Arshad H., Artesani M. C., Asayag E., Avolio F., Azhari K., Baiardini I., Bajrovic N., Bakakos P., Bakeyala Mongono S., Balotro-Torres C., Barba S., Barbara C., Barbosa E., Barreto B., Bartra J., Bateman E. D., Battur L., Bedbrook A., Bedolla Barajas M., Beghe B., Bel E., Ben Kheder A., Benson M., Berghea C., Bergmann K. -C., Bernstein D., Bewick M., Bialek S., Bialoszewski A., Bieber T., Billo N., Bilo M. B., Bindslev-Jensen C., Bjermer L., Bochenska Marciniak M., Bond C., Boner A., Bonini M., Bonini S., Bosnic-Anticevich S., Bosse I., Botskariova S., Bouchard J., Boulet L. -P., Bourret R., Bousquet P., Braido F., Briggs A., Brightling C., Brozek J., Buhl R., Bumbacea R., Burguete Cabanas M. T., Bush A., Busse W. W., Buters J., Caballero-Fonseca F., Calderon M. A., Calvo M., Camargos P., Camuzat T., Cano A., Capriles-Hulett A., Caraballo L., Carlsen K. -H., Caro J., Carr W., Carreon-Asuncion F., Carriazo A. M., Casale T., Castor M. A., Castro E., Cecchi L., Cepeda Sarabia A., Chandrasekharan R., Chang Y. -S., Chato-Andeza V., Chatzi L., Chatzidaki C., Chavannes N. H., Chen Y., Cheng L., Chivato T., Chkhartishvili E., Christoff G., Chrystyn H., Chu D. K., Chua A., Chuchalin A., Chung K. F., Ciceran A., Cingi C., Ciprandi G., Cirule I., Coelho A. C., Constantinidis J., Correia De Sousa J., Costa E., Costa D., Costa Dominguez M. D. C., Coste A., Cox L., Cullen J., Custovic A., Cvetkovski B., D'Amato G., Da Silva J., Dahl R., Dahlen S. -E., Daniilidis V., Darjazini Nahhas L., Darsow U., De Blay F., De Guia E., De Los Santos C., De Manuel Keenoy E., De Vries G., Deleanu D., Demoly P., Denburg J., Devillier P., Didier A., Dimou M., Dinh-Xuan A. T., Djukanovic R., Dokic D., Dominguez Silva M. G., Douagui H., Douladiris N., Doulaptsi M., Dray G., Dubakiene R., Durham S., Dykewicz M., Ebo D., Edelbaher N., Eklund P., El-Gamal Y., El-Sayed Z. A., El-Sayed S. S., El-Seify M., Emuzyte R., Enecilla L., Espinoza H., Espinoza Contreras J. G., Farrell J., Fernandez L., Fink Wagner A., Fiocchi A., Fokkens W. J., Fontaine J. -F., Forastiere F., Fuentes Perez J. M., Gaerlan-Resureccion E., Gaga M., Galvez Romero J. L., Gamkrelidze A., Garcia A., Garcia Cobas C. Y., Garcia Cruz M. D. L. L. H., Gayraud J., Gemicioglu B., Genova S., Gereda J., Gerth Van Wijk R., Gomez M., Gonzalez Diaz S., Gotua M., Grigoreas C., Grisle I., Guidacci M., Guldemond N., Gutter Z., Guzman A., Halloum R., Hamelmann E., Hammadi S., Harvey R., Heinrich J., Hejjaoui A., Hellquist-Dahl B., Hernandez Velazquez L., Hew M., Hossny E., Howarth P., Hrubisko M., Huerta Villalobos Y. R., Humbert M., Hyland M., Ibrahim M., Ilyina N., Irani C., Ispayeva Z., Jares E., Jarvis D., Jassem E., Jenko K., Jimeneracruz Uscanga R. D., Johnston S., Joos G., Jost M., Julge K., Jung K. -S., Just J., Kaidashev I., Kalayci O., Kalyoncu F., Kapsali J., Kardas P., Karjalainen J., Kasala C. A., Katotomichelakis M., Kazi B., Keil T., Keith P., Khaitov M., Khaltaev N., Kim Y. -Y., Kleine-Tebbe J., Koffi N'Goran B., Kompoti E., Kopac P., Koppelman G., Koren Jeverica A., Kosnik M., Kostov K. V., Kowalski M. L., Kralimarkova T., Kramer Vrscaj K., Kraxner H., Kreft S., Kritikos V., Kudlay D., Kull I., Kupczyk M., Kvedariene V., Kyriakakou M., Lalek N., Lane S., Latiff A., Lau S., Lavrut J., Le L., Lessa M., Levin M., Li J., Lieberman P., Liotta G., Lipworth B., Liu X., Lobo R., Lodrup Carlsen K. C., Lombardi C., Louis R., Loukidis S., Lourenco O., Luna Pech J. A., Madjar B., Magnan A., Mahboub B., Mair A., Mais Y., Maitland Van Der Zee A. -H., Makela M., Makris M., Malling H. -J., Mandajieva M., Manning P., Manousakis M., Maragoudakis P., Marshall G., Martinsmartins P., Masjedi M. R., Maspero J. F., Matta Campos J. J., Maurer M., Mavale-Manuel S., Meco C., Melen E., Melo-Gomes E., Meltzer E. O., Menditto E., Menzies-Gow A., Merk H., Michel J. -P., Miculinic N., Midao L., Mihaltan F., Mikael K., Mikos N., Milenkovic B., Mitsias D., Moalla B., Moda G., Mogica Martinez M. D., Mohammad Y., Moin M., Molimard M., Momas I., Monaco A., Montefort S., Mora D., Morais-Almeida M., Mosges R., Mostafa B. E., Munter L., Muraro A., Murray R., Mustakov T., Naclerio R., Nadif R., Nakonechna A., Namazova-Baranova L., Navarro-Locsin G., Neffen H., Nekam K., Neou A., Nicod L., Niederberger-Leppin V., Niedoszytko M., Nieto A., Novellino E., Nunes E., Nyembue D., O'Hehir R., Odjakova C., Ohta K., Okamoto Y., Okubo K., Oliver B., Onorato G. L., Orru M. P., Ouedraogo S., Ouoba K., Paggiaro P. L., Pagkalos A., Palaniappan S. P., Pali-Scholl I., Palkonen S., Palmer S., Panaitescu Bunu C., Panzner P., Papanikolaou V., Papi A., Paralchev B., Paraskevopoulos G., Park H. S., Passalacqua G., Patella V., Pavord I., Pawankar R., Pedersen S., Peleve S., Pereira A., Perez T., Pham-Thi N., Pigearias B., Pin I., Piskou K., Pitsios C., Pitsios K., Plavec D., Poethig D., Pohl W., Poplas Susic A., Popov T. A., Portejoie F., Potter P., Poulsen L., Prados-Torres A., Prarros F., Price D., Prokopakis E., Puy R., Rabe K., Raciborski F., Ramos J., Recto M. T., Reda S. M., Regateiro F., Reider N., Reitsma S., Repka-Ramirez S., Rimmer J., Rivero Yeverino D., Rizzo J. A., Robalo-Cordeiro C., Roberts G., Roche N., Rodriguez Gonzalez M., Rodriguez Zagal E., Rolland C., Roller-Wirnsberger R., Roman Rodriguez M., Romano A., Rombaux P., Romualdez J., Rosado-Pinto J., Rosario N., Rosenwasser L., Rottem M., Rouadi P., Rovina N., Rozman Sinur I., Ruiz M., Ruiz Segura L. T., Ryan D., Sagara H., Sakai D., Sakurai D., Saleh W., Salimaki J., Salina H., Samitas K., Sanchez Coronel M. G., Sanchez-Borges M., Sanchez-Lopez J., Sarafoleanu C., Sarquis Serpa F., Sastre-Dominguez J., Scadding G., Scheire S., Schmid-Grendelmeier P., Schuhl J. F., Schunemann H., Schvalbova M., Scichilone N., Sepulveda C., Serrano E., Sheikh A., Shields M., Shishkov V., Siafakas N., Simeonov A., Simons E. F., Sisul J. C., Sitkauskiene B., Skrindo I., Soklic Kosak T., Sole D., Sooronbaev T., Soto-Martinez M., Sova M., Spertini F., Spranger O., Stamataki S., Stefanaki L., Stellato C., Stelmach R., Sterk P., Strandberg T., Stute P., Subramaniam A., Suppli Ulrik C., Sutherland M., Sylvestre S., Syrigou A., Taborda Barata L., Takovska N., Tan R., Tan F., Tan V., Tang I. P., Taniguchi M., Tannert L., Tattersall J., Teixeira M. D. C., Thijs C., Thomas M., To T., Todo-Bom A. M., Togias A., Tomazic P. -V., Toppila-Salmi S., Toskala E., Triggiani M., Triller N., Triller K., Tsiligianni I., Ulmeanu R., Urbancic J., Urrutia Pereira M., Vachova M., Valdes F., Valenta R., Valentin Rostan M., Valero A., Vallianatou M., Valovirta E., Van Eerd M., Van Ganse E., Van Hage M., Vandenplas O., Vasankari T., Vassileva D., Ventura M. T., Vera-Munoz C., Vicheva D., Vichyanond P., Vidgren P., Viegi G., Vogelmeier C., Von Hertzen L., Vontetsianos T., Vourdas D., Wagenmann M., Walker S., Wallace D., Wang D. Y., Waserman S., Wickman M., Williams S., Williams D., Wilson N., Woo K., Wright J., Wroczynski P., Xepapadaki P., Yakovliev P., Yamaguchi M., Yan K., Yap Y. Y., Yawn B., Yiallouros P., Yoshihara S., Young I., Yusuf O. B., Zaidi A., Zaitoun F., Zar H., Zernotti M., Zhang L., Zhong N., Zidarn M., Zubrinich C., UCL - (MGD) Service de pneumologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, Bousquet J., Anto J.M., Iaccarino G., Czarlewski W., Haahtela T., Anto A., Akdis C.A., Blain H., Canonica G.W., Cardona V., Cruz A.A., Illario M., Ivancevich J.C., Jutel M., Klimek L., Kuna P., Laune D., Larenas-linnemann D., Mullol J., Papadopoulos N.G., Pfaar O., Samolinski B., Valiulis A., Yorgancioglu A., Zuberbier T., Abdul Latiff A.H., Abdullah B., Aberer W., Abusada N., Adcock I., Afani A., Agache I., Aggelidis X., Agustin J., Akdis C., Akdis M., Al-Ahmad M., Bassam A.A.-Z., Aldrey-Palacios O., Cuesta E.A., Alzaabi A., Amad S., Ambrocio G., Annesi-Maesano I., Ansotegui I., Anto J., Arshad H., Artesani M.C., Asayag E., Avolio F., Azhari K., Baiardini I., Bajrovic N., Bakakos P., Mongono S.B., Balotro-Torres C., Barba S., Barbara C., Barbosa E., Barreto B., Bartra J., Bateman E.D., Battur L., Bedbrook A., Barajas M.B., Beghe B., Bel E., Kheder A.B., Benson M., Berghea C., Bergmann K.-C., Bernstein D., Bewick M., Bialek S., Bialoszewski A., Bieber T., Billo N., Bilo M.B., Bindslev-Jensen C., Bjermer L., Marciniak M.B., Bond C., Boner A., Bonini M., Bonini S., Bosnic-Anticevich S., Bosse I., Botskariova S., Bouchard J., Boulet L.-P., Bourret R., Bousquet P., Braido F., Briggs A., Brightling C., Brozek J., Buhl R., Bumbacea R., Cabanas M.T.B., Bush A., Busse W.W., Buters J., Caballero-Fonseca F., Calderon M.A., Calvo M., Camargos P., Camuzat T., Cano A., Capriles-Hulett A., Caraballo L., Carlsen K.-H., Caro J., Carr W., Carreon-Asun-cion F., Carriazo A.M., Casale T., Castor M.A., Castro E., Cecchi L., Sarabia A.C., Chandrasekharan R., Chang Y.-S., Chato-Andeza V., Chatzi L., Chatzidaki C., Chavannes N.H., Chen Y., Cheng L., Chivato T., Chkhartishvili E., Christoff G., Chrystyn H., Chu D.K., Chua A., Chuchalin A., Chung K.F., Ciceran A., Cingi C., Ciprandi G., Cirule I., Coelho A.C., Constantinidis J., de Sousa J.C., Costa E., Costa D., Dominguez M.C.C., Coste A., Cox L., Cullen J., Custovic A., Cvetkovski B., D'amato G., Silva J.D., Dahl R., Dahlen S.-E., Daniilidis V., Nahhas L.D., Darsow U., Blay F., Guia E.D., Santos C., Keenoy E.D.M., Vries G.D., Deleanu D., Demoly P., Denburg J., Devillier P., Didier A., Dimou M., Dinh-Xuan A.T., Djukanovic R., Dokic D., Dominguez Silva M.G., Douagui H., Douladiris N., Doulaptsi M., Dray G., Dubakiene R., Durham S., Dykewicz M., Ebo D., Edelbaher N., Eklund P., El-Gamal Y., El-Sayed Z.A., El-Sayed S.S., El-Seify M., Emuzyte R., Enecilla L., Espinoza H., Guillermo J., Contreras E., Farrell J., Fernandez L., Wagner A.F., Fiocchi A., Fokkens W.J., Fontaine J.-F., Forastiere F., Perez J.M.F., Gaerlan-resureccion E., Gaga M., Romero J.L.G., Gamkrelidze A., Garcia A., Cobas C.Y.G., Garcia Cruz M.L.L.H., Gayraud J., Gemicioglu B., Genova S., Gereda J., Wijk R.G., Gomez M., Diaz S.G., Gotua M., Grigoreas C., Grisle I., Guidacci M., Guldemond N., Gutter Z., Guzman A., Halloum R., Hamelmann E., Hammadi S., Harvey R., Heinrich J., Hejjaoui A., Hellquist-Dahl B., Velazquez L.H., Hew M., Hossny E., Howarth P., Hrubisko M., Villalobos Y.R.H., Humbert M., Hyland M., Ibrahim M., Ilyina N., Irani C., Ispayeva Z., Jares E., Jarvis D., Jassem E., Jenko K., Uscanga R.D.J., Johnston S., Joos G., Jost M., Julge K., Jung K.-S., Just J., Kaidashev I., Kalayci O., Kalyoncu F., Kapsali J., Kardas P., Karjalainen J., Kasala C.A., Katotomichelakis M., Kazi B., Keil T., Keith P., Khaitov M., Khaltaev N., Kim Y.-Y., Kleine-Tebbe J., Koffi N'Goran B., Kompoti E., Kopac P., Koppelman G., Jeverica A.K., Kosnik M., Kostov K.V., Kowalski M.L., Kralimarkova T., Vrscaj K.K., Kraxner H., Kreft S., Kritikos V., Kudlay D., Kull I., Kupczyk M., Kvedariene V., Kyriakakou M., Lalek N., Lane S., Larenas-Linnemann D., Latiff A., Lau S., Lavrut J., Le L., Lessa M., Levin M., Li J., Lieberman P., Liotta G., Lipworth B., Liu X., Lobo R., Lodrup Carlsen K.C., Lombardi C., Louis R., Loukidis S., Lourenco O., Luna Pech J.A., Madjar B., Magnan A., Mahboub B., Mair A., Mais Y., van der Zee A.-H.M., Makela M., Makris M., Malling H.-J., Mandajieva M., Manning P., Manousakis M., Maragoudakis P., Marshall G., Martins P., Reza Masjedi M., Maspero J.F., Campos J.J.M., Maurer M., Mavale-Manuel S., Meco C., Melen E., Melo-Gomes E., Meltzer E.O., Menditto E., Menzies-Gow A., Merk H., Michel J.-P., Miculinic N., Midao L., Mihaltan F., Mikael K., Mikos N., Milenkovic B., Mitsias D., Moalla B., Moda G., Martinez M.D.M., Mohammad Y., Moin M., Molimard M., Momas I., Monaco A., Montefort S., Mora D., Morais-Almeida M., Mosges R., Mostafa B.E., Munter L., Muraro A., Murray R., Mustakov T., Naclerio R., Nadif R., Nakonechna A., Namazova-Baranova L., Navarro-Locsin G., Neffen H., Nekam K., Neou A., Nicod L., Niederberger-Leppin V., Niedoszytko M., Nieto A., Novellino E., Nunes E., Nyembue D., O'hehir R., Odjakova C., Ohta K., Okamoto Y., Okubo K., Oliver B., Onorato G.L., Orru M.P., Ouedraogo S., Ouoba K., Paggiaro P.L., Pagkalos A., Palaniappan S.P., Pali-Scholl I., Palkonen S., Palmer S., Bunu C.P., Panzner P., Papanikolaou V., Papi A., Paralchev B., Paraskevopoulos G., Park H.S., Passalacqua G., Patella V., Pavord I., Pawankar R., Pedersen S., Peleve S., Pereira A., Perez T., Pham-Thi N., Pigearias B., Pin I., Piskou K., Pitsios C., Pitsios K., Plavec D., Poethig D., Pohl W., Susic A.P., Popov T.A., Portejoie F., Potter P., Poulsen L., Prados-Torres A., Prarros F., Price D., Prokopakis E., Puy R., Rabe K., Raciborski F., Ramos J., Recto M.T., Reda S.M., Regateiro F., Reider N., Reitsma S., Repka-Ramirez S., Rimmer J., Yeverino D.R., Rizzo J.A., Robalo-Cordeiro C., Roberts G., Roche N., Gonzalez M.R., Zagal E.R., Rolland C., Roller-Wirns-berger R., Rodriguez M.R., Romano A., Rombaux P., Romualdez J., Rosado-Pinto J., Rosario N., Rosenwasser L., Rottem M., Rouadi P., Rovina N., Sinur I.R., Ruiz M., Segura L.T.R., Ryan D., Sagara H., Sakai D., Sakurai D., Saleh W., Salimaki J., Salina H., Samitas K.-N., Coronel M.G.S., Sanchez-Borges M., Sanchez-Lopez J., Sarafoleanu C., Serpa F.S., Sastre-Dominguez J., Scadding G., Scheire S., Schmid-Grendelmeier P., Schuhl J.F., Schunemann H., Schvalbova M., Scichilone N., Sepulveda C., Serrano E., Sheikh A., Shields M., Shishkov V., Siafakas N., Simeonov A., Simons E.F., Sisul J.C., Sitkauskiene B., Skrindo I., Kosak T.S., Sole D., Sooronbaev T., Soto-Martinez M., Sova M., Spertini F., Spranger O., Stamataki S., Stefanaki L., Stellato C., Stelmach R., Sterk P., Strandberg T., Stute P., Subramaniam A., Suppli Ulrik C., Sutherland M., Sylvestre S., Syrigou A., Barata L.T., Takovska N., Tan R., Tan F., Tan V., Tang I.P., Taniguchi M., Tannert L., Tattersall J., Teixeira M.D.C., Thijs C., Thomas M., To T., Todo-Bom A.M., Togias A., Tomazic P.-V., Toppila-Salmi S., Toskala E., Triggiani M., Triller N., Triller K., Tsiligianni I., Ulmeanu R., Urbancic J., Pereira M.U., Vachova M., Valdes F., Valenta R., Rostan M.V., Valero A., Vallianatou M., Valovirta E., Eerd M.V., Ganse E.V., Hage M., Vandenplas O., Vasankari T., Vassileva D., Ventura T., Vera-Munoz C., Vicheva D., Vichyanond P., Vidgren P., Viegi G., Vogelmeier C., Hertzen L.V., Vontetsianos T., Vourdas D., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Wickman M., Williams S., Williams D., Wilson N., Woo K., Wright J., Wroczynski P., Xepapadaki P., Yakovliev P., Yamaguchi M., Yan K., Yap Y.Y., Yawn B., Yiallouros P., Yoshihara S., Young I., Yusuf O.B., Zaidi A., Zaitoun F., Zar H., Zernotti M., Zhang L., Zhong N., Zidarn M., Zubrinich C., Dubakienė, Rūta, Ėmužytė, Regina, Kvedarienė, Violeta, Bousquet, J., Anto, J. M., Iaccarino, G., Czarlewski, W., Haahtela, T., Anto, A., Akdis, C. A., Blain, H., Canonica, G. W., Cardona, V., Cruz, A. A., Illario, M., Ivancevich, J. C., Jutel, M., Klimek, L., Kuna, P., Laune, D., Larenas-Linnemann, D., Mullol, J., Papadopoulos, N. G., Pfaar, O., Samolinski, B., Valiulis, A., Yorgancioglu, A., Zuberbier, T., Abdul Latiff, A. H., Abdullah, B., Aberer, W., Abusada, N., Adcock, I., Afani, A., Agache, I., Aggelidis, X., Agustin, J., Akdis, C., Akdis, M., Al-Ahmad, M., Al-Zahab Bassam, A., Aldrey-Palacios, O., Alvarez Cuesta, E., Alzaabi, A., Amad, S., Ambrocio, G., Annesi-Maesano, I., Ansotegui, I., Anto, J., Arshad, H., Artesani, M. C., Asayag, E., Avolio, F., Azhari, K., Baiardini, I., Bajrovic, N., Bakakos, P., Bakeyala Mongono, S., Balotro-Torres, C., Barba, S., Barbara, C., Barbosa, E., Barreto, B., Bartra, J., Bateman, E. D., Battur, L., Bedbrook, A., Bedolla Barajas, M., Beghe, B., Bel, E., Ben Kheder, A., Benson, M., Berghea, C., Bergmann, K. -C., Bernstein, D., Bewick, M., Bialek, S., Bialoszewski, A., Bieber, T., Billo, N., Bilo, M. B., Bindslev-Jensen, C., Bjermer, L., Bochenska Marciniak, M., Bond, C., Boner, A., Bonini, M., Bonini, S., Bosnic-Anticevich, S., Bosse, I., Botskariova, S., Bouchard, J., Boulet, L. -P., Bourret, R., Bousquet, P., Braido, F., Briggs, A., Brightling, C., Brozek, J., Buhl, R., Bumbacea, R., Burguete Cabanas, M. T., Bush, A., Busse, W. W., Buters, J., Caballero-Fonseca, F., Calderon, M. A., Calvo, M., Camargos, P., Camuzat, T., Cano, A., Capriles-Hulett, A., Caraballo, L., Carlsen, K. -H., Caro, J., Carr, W., Carreon-Asuncion, F., Carriazo, A. M., Casale, T., Castor, M. A., Castro, E., Cecchi, L., Cepeda Sarabia, A., Chandrasekharan, R., Chang, Y. -S., Chato-Andeza, V., Chatzi, L., Chatzidaki, C., Chavannes, N. H., Chen, Y., Cheng, L., Chivato, T., Chkhartishvili, E., Christoff, G., Chrystyn, H., Chu, D. K., Chua, A., Chuchalin, A., Chung, K. F., Ciceran, A., Cingi, C., Ciprandi, G., Cirule, I., Coelho, A. C., Constantinidis, J., Correia De Sousa, J., Costa, E., Costa, D., Costa Dominguez, M. D. C., Coste, A., Cox, L., Cullen, J., Custovic, A., Cvetkovski, B., D'Amato, G., Da Silva, J., Dahl, R., Dahlen, S. -E., Daniilidis, V., Darjazini Nahhas, L., Darsow, U., De Blay, F., De Guia, E., De Los Santos, C., De Manuel Keenoy, E., De Vries, G., Deleanu, D., Demoly, P., Denburg, J., Devillier, P., Didier, A., Dimou, M., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Dominguez Silva, M. G., Douagui, H., Douladiris, N., Doulaptsi, M., Dray, G., Dubakiene, R., Durham, S., Dykewicz, M., Ebo, D., Edelbaher, N., Eklund, P., El-Gamal, Y., El-Sayed, Z. A., El-Sayed, S. S., El-Seify, M., Emuzyte, R., Enecilla, L., Espinoza, H., Espinoza Contreras, J. G., Farrell, J., Fernandez, L., Fink Wagner, A., Fiocchi, A., Fokkens, W. J., Fontaine, J. -F., Forastiere, F., Fuentes Perez, J. M., Gaerlan-Resureccion, E., Gaga, M., Galvez Romero, J. L., Gamkrelidze, A., Garcia, A., Garcia Cobas, C. Y., Garcia Cruz, M. D. L. L. H., Gayraud, J., Gemicioglu, B., Genova, S., Gereda, J., Gerth Van Wijk, R., Gomez, M., Gonzalez Diaz, S., Gotua, M., Grigoreas, C., Grisle, I., Guidacci, M., Guldemond, N., Gutter, Z., Guzman, A., Halloum, R., Hamelmann, E., Hammadi, S., Harvey, R., Heinrich, J., Hejjaoui, A., Hellquist-Dahl, B., Hernandez Velazquez, L., Hew, M., Hossny, E., Howarth, P., Hrubisko, M., Huerta Villalobos, Y. R., Humbert, M., Hyland, M., Ibrahim, M., Ilyina, N., Irani, C., Ispayeva, Z., Jares, E., Jarvis, D., Jassem, E., Jenko, K., Jimeneracruz Uscanga, R. D., Johnston, S., Joos, G., Jost, M., Julge, K., Jung, K. -S., Just, J., Kaidashev, I., Kalayci, O., Kalyoncu, F., Kapsali, J., Kardas, P., Karjalainen, J., Kasala, C. A., Katotomichelakis, M., Kazi, B., Keil, T., Keith, P., Khaitov, M., Khaltaev, N., Kim, Y. -Y., Kleine-Tebbe, J., Koffi N'Goran, B., Kompoti, E., Kopac, P., Koppelman, G., Koren Jeverica, A., Kosnik, M., Kostov, K. V., Kowalski, M. L., Kralimarkova, T., Kramer Vrscaj, K., Kraxner, H., Kreft, S., Kritikos, V., Kudlay, D., Kull, I., Kupczyk, M., Kvedariene, V., Kyriakakou, M., Lalek, N., Lane, S., Latiff, A., Lau, S., Lavrut, J., Le, L., Lessa, M., Levin, M., Li, J., Lieberman, P., Liotta, G., Lipworth, B., Liu, X., Lobo, R., Lodrup Carlsen, K. C., Lombardi, C., Louis, R., Loukidis, S., Lourenco, O., Luna Pech, J. A., Madjar, B., Magnan, A., Mahboub, B., Mair, A., Mais, Y., Maitland Van Der Zee, A. -H., Makela, M., Makris, M., Malling, H. -J., Mandajieva, M., Manning, P., Manousakis, M., Maragoudakis, P., Marshall, G., Martinsmartins, P., Masjedi, M. R., Maspero, J. F., Matta Campos, J. J., Maurer, M., Mavale-Manuel, S., Meco, C., Melen, E., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Menzies-Gow, A., Merk, H., Michel, J. -P., Miculinic, N., Midao, L., Mihaltan, F., Mikael, K., Mikos, N., Milenkovic, B., Mitsias, D., Moalla, B., Moda, G., Mogica Martinez, M. D., Mohammad, Y., Moin, M., Molimard, M., Momas, I., Monaco, A., Montefort, S., Mora, D., Morais-Almeida, M., Mosges, R., Mostafa, B. E., Munter, L., Muraro, A., Murray, R., Mustakov, T., Naclerio, R., Nadif, R., Nakonechna, A., Namazova-Baranova, L., Navarro-Locsin, G., Neffen, H., Nekam, K., Neou, A., Nicod, L., Niederberger-Leppin, V., Niedoszytko, M., Nieto, A., Novellino, E., Nunes, E., Nyembue, D., O'Hehir, R., Odjakova, C., Ohta, K., Okamoto, Y., Okubo, K., Oliver, B., Onorato, G. L., Orru, M. P., Ouedraogo, S., Ouoba, K., Paggiaro, P. L., Pagkalos, A., Palaniappan, S. P., Pali-Scholl, I., Palkonen, S., Palmer, S., Panaitescu Bunu, C., Panzner, P., Papanikolaou, V., Papi, A., Paralchev, B., Paraskevopoulos, G., Park, H. S., Passalacqua, G., Patella, V., Pavord, I., Pawankar, R., Pedersen, S., Peleve, S., Pereira, A., Perez, T., Pham-Thi, N., Pigearias, B., Pin, I., Piskou, K., Pitsios, C., Pitsios, K., Plavec, D., Poethig, D., Pohl, W., Poplas Susic, A., Popov, T. A., Portejoie, F., Potter, P., Poulsen, L., Prados-Torres, A., Prarros, F., Price, D., Prokopakis, E., Puy, R., Rabe, K., Raciborski, F., Ramos, J., Recto, M. T., Reda, S. M., Regateiro, F., Reider, N., Reitsma, S., Repka-Ramirez, S., Rimmer, J., Rivero Yeverino, D., Rizzo, J. A., Robalo-Cordeiro, C., Roberts, G., Roche, N., Rodriguez Gonzalez, M., Rodriguez Zagal, E., Rolland, C., Roller-Wirnsberger, R., Roman Rodriguez, M., Romano, A., Rombaux, P., Romualdez, J., Rosado-Pinto, J., Rosario, N., Rosenwasser, L., Rottem, M., Rouadi, P., Rovina, N., Rozman Sinur, I., Ruiz, M., Ruiz Segura, L. T., Ryan, D., Sagara, H., Sakai, D., Sakurai, D., Saleh, W., Salimaki, J., Salina, H., Samitas, K., Sanchez Coronel, M. G., Sanchez-Borges, M., Sanchez-Lopez, J., Sarafoleanu, C., Sarquis Serpa, F., Sastre-Dominguez, J., Scadding, G., Scheire, S., Schmid-Grendelmeier, P., Schuhl, J. F., Schunemann, H., Schvalbova, M., Scichilone, N., Sepulveda, C., Serrano, E., Sheikh, A., Shields, M., Shishkov, V., Siafakas, N., Simeonov, A., Simons, E. F., Sisul, J. C., Sitkauskiene, B., Skrindo, I., Soklic Kosak, T., Sole, D., Sooronbaev, T., Soto-Martinez, M., Sova, M., Spertini, F., Spranger, O., Stamataki, S., Stefanaki, L., Stellato, C., Stelmach, R., Sterk, P., Strandberg, T., Stute, P., Subramaniam, A., Suppli Ulrik, C., Sutherland, M., Sylvestre, S., Syrigou, A., Taborda Barata, L., Takovska, N., Tan, R., Tan, F., Tan, V., Tang, I. P., Taniguchi, M., Tannert, L., Tattersall, J., Teixeira, M. D. C., Thijs, C., Thomas, M., To, T., Todo-Bom, A. M., Togias, A., Tomazic, P. -V., Toppila-Salmi, S., Toskala, E., Triggiani, M., Triller, N., Triller, K., Tsiligianni, I., Ulmeanu, R., Urbancic, J., Urrutia Pereira, M., Vachova, M., Valdes, F., Valenta, R., Valentin Rostan, M., Valero, A., Vallianatou, M., Valovirta, E., Van Eerd, M., Van Ganse, E., Van Hage, M., Vandenplas, O., Vasankari, T., Vassileva, D., Ventura, M. T., Vera-Munoz, C., Vicheva, D., Vichyanond, P., Vidgren, P., Viegi, G., Vogelmeier, C., Von Hertzen, L., Vontetsianos, T., Vourdas, D., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Wickman, M., Williams, S., Williams, D., Wilson, N., Woo, K., Wright, J., Wroczynski, P., Xepapadaki, P., Yakovliev, P., Yamaguchi, M., Yan, K., Yap, Y. Y., Yawn, B., Yiallouros, P., Yoshihara, S., Young, I., Yusuf, O. B., Zaidi, A., Zaitoun, F., Zar, H., Zernotti, M., Zhang, L., Zhong, N., Zidarn, M., Zubrinich, C., University of Zurich, Bousquet, Jean, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Berlin Institute of Health (BIH), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, IMIM-Hospital del Mar, Generalitat de Catalunya, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), 'Federico II' University of Naples Medical School, Medical Consulting Czarlewski, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Euromov (EuroMov), Université de Montpellier (UM), IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy., Vall d'Hebron University Hospital [Barcelona], ProAR – Nucleo de Excelencia em Asma, Universidade Federal da Bahia (UFBA), Global Alliance Against Chronic Respiratory Diseases (GARD-WHO), Division for Health Innovation, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Wrocław Medical University, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Barlicki University Hospital, KYomed INNOV [Montpellier], Hospital Medica Sur [Mexico City, Mexico], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Royal Manchester Children's Hospital, University of Manchester [Manchester], General Children's Hospital of Athens P & A Kyriakou, Philipps Universität Marburg = Philipps University of Marburg, Medical University of Warsaw - Poland, Vilnius University [Vilnius], Manisa Celal Bayar University, and Salvy-Córdoba, Nathalie

Subjects
BLOOD-PRESSURE, Review, Angiotensin-converting enzyme, Antioxidant, Coronavirus, Diet, Food, law.invention, Dietary interventions, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 10183 Swiss Institute of Allergy and Asthma Research, law, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, education.field_of_study, Mortality rate, 3. Good health, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, 2723 Immunology and Allergy, Angiotensin-converting enzyme, Antioxidant, Coronavirus, Diet, Food, Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Coronaviru, Immunology, Population, 610 Medicine & health, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, Environmental health, population, angiotensin-converting enzyme, Quarantine, education, 2403 Immunology, ANTIHYPERTENSIVE PEPTIDES, business.industry, RC581-607, GENE, POLYMORPHISM, [SDV.AEN] Life Sciences [q-bio]/Food and Nutrition, 030228 respiratory system, 2740 Pulmonary and Respiratory Medicine, Immunologic diseases. Allergy, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Regional differences, Coronavirus Infections
Abstract

Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.

Published
2020

43. S3 guideline Allergy Prevention

Author

Kopp, M., V, Muche-Borowski, C., Abou-Dakn, M., Ahrens, B., Beyer, K., Blumchen, K., Bubel, P., Chaker, A., Cremer, M., Ensenauer, R., Gerstlauer, M., Gieler, U., Hubner, I. M., Horak, F., Klimek, L., Koletzko, B., V, Koletzko, S., Lau, S., Lob-Corzilius, T., Nemat, K., Peters, E. M. J., Pizzulli, A., Reese, I, Rolinck-Werninghaus, C., Rouw, E., Schaub, B., Schmidt, S., Steiss, J. O., Striegel, A. K., Szepfalusi, Z., Schlembach, D., Spindler, T., Taube, C., Trendelenburg, V, Treudler, R., Umpfenbach, U., Vogelberg, C., Wagenmann, M., Weissenborn, A., Werfel, T., Worm, M., Sitter, H., Hamelmann, E., Kopp, M., V, Muche-Borowski, C., Abou-Dakn, M., Ahrens, B., Beyer, K., Blumchen, K., Bubel, P., Chaker, A., Cremer, M., Ensenauer, R., Gerstlauer, M., Gieler, U., Hubner, I. M., Horak, F., Klimek, L., Koletzko, B., V, Koletzko, S., Lau, S., Lob-Corzilius, T., Nemat, K., Peters, E. M. J., Pizzulli, A., Reese, I, Rolinck-Werninghaus, C., Rouw, E., Schaub, B., Schmidt, S., Steiss, J. O., Striegel, A. K., Szepfalusi, Z., Schlembach, D., Spindler, T., Taube, C., Trendelenburg, V, Treudler, R., Umpfenbach, U., Vogelberg, C., Wagenmann, M., Weissenborn, A., Werfel, T., Worm, M., Sitter, H., and Hamelmann, E.

Abstract

Background: The persistently high prevalence of allergic diseases in Western industrial nations and the limited possibilities of causal therapy make evidence-based recommendations for primary prevention necessary. Methods: The recommendations of the S3 guideline Allergy Prevention, published in its last version in 2014, were revised and consulted on the basis of a current systematic literature search. The evidence search was conducted for the period 06/2013 - 11/2020 in the electronic databases Cochrane and MEDLINE, as well as in the reference lists of current reviews and through references from experts. The literature found was screened in two filtering processes, first by title and abstract, and the remaining papers were screened in the full text for relevance. The studies included after this were sorted by level of evidence, and the study quality was indicated in terms of potential bias (low/high). The revised recommendations were formally agreed and consented upon with the participation of representatives of the relevant professional societies and (self-help) organizations (nominal group process). Of 5,681 hits, 286 studies were included and assessed. Results: Recommendations on maternal nutrition during pregnancy and breastfeeding as well as on infant nutrition in the first months of life again play an important role in the updated guideline: Many of the previous recommendations were confirmed by the current data. It was specified that breastfeeding should be exclusive for the first 4 - 6 months after birth, if possible, and that breastfeeding should continue with the introduction of complementary foods. A new recommendation is that supplementary feeding of cow's milk-based formula should be avoided in the first days of life if the mother wishes to breastfeed. Furthermore, it was determined that the evidence for a clear recommendation for hydrolyzed infant formula in non-breastfed infants at risk is currently no longer sufficient. It is therefore currently reco

Published
2022

44. Allergy in severe asthma

Author

Del Giacco, S. R., Bakirtas, A., Bel, E., Custovic, A., Diamant, Z., Hamelmann, E., Heffler, E., Kalayci, Ö., Saglani, S., Sergejeva, S., Seys, S., Simpson, A., and Bjermer, L.

Published
2017
Full Text
View/download PDF

45. S3-Leitlinie Allergieprävention

Author

Kopp, M.V., primary, Muche-Borowski, C., additional, Abou-Dakn, M., additional, Ahrens, B., additional, Beyer, K., additional, Blümchen, K., additional, Bubel, P., additional, Chaker, A., additional, Cremer, M., additional, Ensenauer, R., additional, Gerstlauer, M., additional, Gieler, U., additional, Hübner, I.M., additional, Horak, F., additional, Klimek, L., additional, Koletzko, B.V., additional, Koletzko, S., additional, Lau, S., additional, Lob-Corzilius, T., additional, Nemat, K., additional, Peters, E.M.J., additional, Pizzulli, A., additional, Reese, I., additional, Rolinck-Werninghaus, C., additional, Rouw, E., additional, Schaub, B., additional, Schmidt, S., additional, Steiß, J.O., additional, Striegel, A.K., additional, Szépfalusi, Z., additional, Schlembach, D., additional, Spindler, T., additional, Taube, C., additional, Trendelenburg, V., additional, Treudler, R., additional, Umpfenbach, U., additional, Vogelberg, C., additional, Wagenmann, M., additional, Weißenborn, A., additional, Werfel, T., additional, Worm, M., additional, Sitter, H., additional, and Hamelmann, E., additional

Published
2022
Full Text
View/download PDF

47. Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, ÖGAI, LGAI, ÖGP, ARIA und EAACI

Author

Klimek, L., Pfaar, O., Worm, M., Eiwegger, T., Hagemann, J., Ollert, M., Untersmayr, E., Hoffmann-Sommergruber, K., Vultaggio, A., Agache, I., Bavbek, S., Bossios, A., Casper, I., Chan, S., Chatzipetrou, A., Vogelberg, C., Firinu, D., Kauppi, P., Kolios, A., Kothari, A., Matucci, A., Palomares, O., Szépfalusi, Z., Pohl, W., Hötzenecker, W., Rosenkranz, A. R., Bergmann, K. C., Bieber, T., Buhl, R., Buters, J., Darsow, U., Keil, T., Kleine-Tebbe, J., Lau, S., Maurer, M., Merk, H., Mösges, R., Saloga, J., Staubach, P., Jappe, U., Rabe, K. F., Rabe, U., Vogelmeier, C., Biedermann, T., Jung, K., Schlenter, W., Ring, J., Chaker, A., Wehrmann, W., Becker, S., Freudelsperger, L., Mülleneisen, N., Nemat, K., Czech, W., Wrede, H., Brehler, R., Fuchs, T., Tomazic, P. V., Aberer, W., Fink-Wagner, A. H., Horak, F., Wöhrl, S., Niederberger-Leppin, V., Pali-Schöll, I., Roller-Wirnsberger, R., Spranger, O., Valenta, R., Akdis, M., Matricardi, P. M., Spertini, F., Khaltaev, N., Michel, J. P., Nicod, L., Schmid-Grendelmeier, P., Idzko, M., Hamelmann, E., Jakob, T., Werfel, T., Wagenmann, M., Taube, C., Jensen-Jarolim, E., Korn, S., Hentges, F., Schwarze, J., O'Mahony, L., Knol, E. F., del Giacco, S., Chivato Pérez, T., Bousquet, J., Zuberbier, T., Akdis, C., and Jutel, M.

Subjects
Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Omalizumab, Dupilumab, Immunoglobulin E, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Reslizumab, Immunology and Allergy, Medicine, 030223 otorhinolaryngology, Mepolizumab, biology, SARS-CoV-2, business.industry, Benralizumab, Telemedicine, 030228 respiratory system, chemistry, Immunology, biology.protein, Covid-19, business, medicine.drug
Published
2020

48. Early priming of asthma and respiratory allergies: Future aspects of prevention: A statement by the European Forum for Education and Research in Allergy and Airway Disease (EUFOREA) and the EAACI-Clemens von Pirquet Foundation

Author

Wahn U, Lau S, Eigenmann P, Melen E, Krauss-Etschmann S, Lex C, Matricardi P, Schaub B, Halken S, Ege M, Jackson D, Hamelmann E, Szépfalusi Z, Garcia AN, and von Mutius E

Subjects
risk factors for allergy, prediction of asthma, asthma prevention, Allergy prevention
Abstract

In order to summarize recent research on the prevention of allergies-particularly asthma-and stimulate new activities for future initiatives, a virtual workshop sponsored by the EAACI Clemens von Pirquet foundation and EUFOREA was held in October 2021. The determinants of the "allergic march" as well as the key messages from intervention studies were reviewed by an international faculty of experts. Several unmet needs were identified, and a number of priorities for future studies were proposed.

Published
2022

49. Microbiome and the development of allergies

Author

Nau, T., Müller, Anne, Übner, Hendrik, and Hamelmann, E.

Subjects
microbial metabolites, probiotics, allergy prevention, atopic eczema, Medizin, Immunology and Allergy, microbiome, asthma, prebiotics
Abstract

The microbiome and its metabolites play an important role in the development of allergies. Since the first description of the "farm effect", many new insights have been gained, but at the same time many questions are still open, and a preventive formula is still a long way ahead. Finding this formula is a central scientific task in this decade. The current state of knowledge already shows that the development of the immune system and the unfolding of the microbiome are closely linked at the beginning of life, first and foremost in the intestine. Dysbiosis or disturbances in the development of the gut microbiota in early childhood contribute to an increased risk of atopy or asthma in later childhood. In the PASTURE study, the maturation of the gut microbiome and the presence of certain microbiome metabolites in the first year of life have been shown to play a significant role in the asthma-protective effect observed in earlier farm studies in children. These studies showed that changes in overall bacterial composition are far more important than the role and presence of individual taxa. Via a gut-lung immune axis, microbial communities appear to be asthma-protective. Relevant microbial metabolites include short-chain fatty acids (SCFA) such as butyrate, which are thought to have particular immunomodulatory roles. Both metabolites have anti-inflammatory and immunomodulatory effects and can thereby reduce inflammatory responses. Products of microbial carbohydrate metabolism may also be protective and are currently being studied in more detail. Overall, it is clear that preventive measures should take place in the first year of life, when the gut microbiome is particularly malleable and susceptible to change. Research on allergy prevention is not standing still, but so far only a few clear recommendations for action can be made. For example, the benefits of the frequently discussed prebiotics and probiotics with regard to allergy prevention are the subject of controversial debate, as the available studies are still somewhat sparse. The highly exciting studies on the role of lipocalins (for example, ss-lactoglobulin), lipopolysaccharide, bacterial lysates, an active ingredient from larval products of the helminth Heligmosomoides polygyrus bakeri, and fungi also look promising and give rise to hope for an effective allergy prevention strategy., Das Mikrobiom und seine Metabolite spielen eine wichtige Rolle in der Entstehung von Allergien. Seit der Erstbeschreibung des „Bauernhof-Effekts“ konnten bereits zahlreiche neue Erkenntnisse gewonnen werden, gleichzeitig sind noch immer viele Fragen offen und eine Art präventive Formel ist noch in weiter Ferne. Diese zu finden, ist in diesem Jahrzehnt eine zentrale wissenschaftliche Aufgabe. Der heutige Wissensstand gibt bereits wieder, dass zu Beginn des Lebens die Entwicklung des Immunsystems und die Entfaltung des Mikrobioms eng miteinander verknüpft sind, allen voran im Darm. Eine Dysbiose bzw. Störungen der Entwicklung der Darmmikrobiota in der frühen Kindheit tragen zu einem erhöhten Atopie- bzw. Asthmarisiko im späteren Kindesalter bei. Mittels der PASTURE-Studie konnte gezeigt werden, dass die Reifung des Darm-Mikrobioms und das Vorhandensein bestimmter Mikrobiom-Metabolite im ersten Lebensjahr einen bedeutenden Anteil am asthmaprotektiven Effekt haben, der in den früheren Bauernhofstudien bei Kindern beobachtet werden konnte. Diese Studien zeigten, dass Veränderungen der bakteriellen Gesamtzusammensetzung weitaus wichtiger sind als die Rolle und Präsenz einzelner Taxa. Über eine Darm-Lungen-Immun-Achse scheinen mikrobielle Gemeinschaften asthmaprotektiv wirken zu können. Relevante mikrobielle Metabolite sind unter anderem kurzkettige Fettsäuren (SCFA) wie Butyrat, denen eine besondere immunmodulatorische Rolle beigemessen wird. Beide Metabolite wirken antiinflammatorisch und immunmodulatorisch und können dadurch Entzündungsreaktionen reduzieren. Auch Produkte des mikrobiellen Kohlenhydratstoffwechsels können eine protektive Wirkung haben und werden aktuell genauer untersucht. Insgesamt wird deutlich, dass Präventionsmaßnahmen im ersten Lebensjahr stattfinden sollten, wenn das Darm-Mikrobiom besonders formbar und beinflussbar für Veränderungen ist. Die Forschung zur Allergieprävention steht nicht still, allerdings lassen sich bislang nur wenige konkrete Handlungsempfehlungen aussprechen. So wird zum Beispiel der Nutzen der oft thematisierten Prä- und Probiotika im Hinblick auf die Allergieprävention kontrovers diskutiert, da die Studienlage noch recht dünn ist. Auch die spannenden Studien zur Rolle von Lipocalinen (z. B. ß-Lactoglobulin), Lipopolysaccharid, bakteriellen Lysaten, einem Wirkstoff aus Larven des Wurmparasiten Heligmosomoides polygyrus bakeri und Pilzen machen einen vielversprechenden Eindruck und geben Anlass zur Hoffnung auf kommende effektive Allergiepräventionsstrategien.

Published
2022

50. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

Author

Zuberbier, T. Abdul Latiff, A.H. Abuzakouk, M. Aquilina, S. Asero, R. Baker, D. Ballmer-Weber, B. Bangert, C. Ben-Shoshan, M. Bernstein, J.A. Bindslev-Jensen, C. Brockow, K. Brzoza, Z. Chong Neto, H.J. Church, M.K. Criado, P.R. Danilycheva, I.V. Dressler, C. Ensina, L.F. Fonacier, L. Gaskins, M. Gáspár, K. Gelincik, A. Giménez-Arnau, A. Godse, K. Gonçalo, M. Grattan, C. Grosber, M. Hamelmann, E. Hébert, J. Hide, M. Kaplan, A. Kapp, A. Kessel, A. Kocatürk, E. Kulthanan, K. Larenas-Linnemann, D. Lauerma, A. Leslie, T.A. Magerl, M. Makris, M. Meshkova, R.Y. Metz, M. Micallef, D. Mortz, C.G. Nast, A. Oude-Elberink, H. Pawankar, R. Pigatto, P.D. Ratti Sisa, H. Rojo Gutiérrez, M.I. Saini, S.S. Schmid-Grendelmeier, P. Sekerel, B.E. Siebenhaar, F. Siiskonen, H. Soria, A. Staubach-Renz, P. Stingeni, L. Sussman, G. Szegedi, A. Thomsen, S.F. Vadasz, Z. Vestergaard, C. Wedi, B. Zhao, Z. Maurer, M.

Subjects
immune system diseases, parasitic diseases, education, skin and connective tissue diseases
Abstract

This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert-guided and evidence-based diagnostic and therapeutic approaches for the different subtypes of urticaria. © 2021 GA²LEN. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results